Tigermed: Net profit expected to increase by 119.15% year-on-year in 2025, proposing a dividend of 1.26 RMB per 10 shares.

2026-04-01 10:27:47

People’s Finance and Information, March 30—Tiger Med (300347) disclosed its annual report on March 30. In 2025, the company achieved operating revenue of 6.833 billion yuan, up 3.48% year over year. Net profit attributable to shareholders was 888 million yuan, up 119.15% year over year. Basic earnings per share were 1.04 yuan. The company plans to distribute a cash dividend of 1.26 yuan for every 10 shares (including tax). During the reporting period, the company’s order demand accelerated compared with 2024. The net new orders (newly signed orders after deducting canceled orders) amounted to 10.16 billion yuan, up 20.7%. In 2025, the average unit price of newly signed orders has stabilized, and it is expected to return to a growth trend in 2026. In 2025, the company actively promoted the overseas sponsors’ early clinical project implementation in China and has made substantial progress with both multinational pharmaceutical companies and overseas biotech firms.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.